Quick Answer
GALECTIN THERAPEUTICS INC reported Stockholders Equity of -$127.92 million for fiscal year 2025.
GALECTIN THERAPEUTICS INC Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$127.92M | -22.1% |
| 2024 | -$104.79M | -69.1% |
| 2023 | -$61.96M | -82.7% |
| 2022 | -$33.92M | -3898.1% |
| 2021 | $893.0K | -96.0% |
| 2020 | $22.47M | -48.8% |
| 2019 | $43.87M | +747.8% |
| 2018 | $5.17M | +1076.4% |
| 2017 | -$530.0K | -105.1% |
| 2016 | $10.29M | -42.9% |
| 2015 | $18.04M | -14.9% |
| 2014 | $21.20M | +1331.1% |
| 2013 | $1.48M | +27.1% |
| 2012 | $1.17M | +154.8% |
| 2011 | -$2.12M | -25.4% |
| 2010 | -$1.69M | +62.1% |
| 2009 | -$4.47M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$125.30M | -33.0% | -5.4% |
| June 30, 2025 | -$118.89M | -41.8% | -4.3% |
| March 31, 2025 | -$113.98M | -156.9% | -8.8% |
| December 31, 2024 | -$104.79M | -69.1% | -11.2% |
| September 30, 2024 | -$94.20M | -79.1% | -12.3% |
| June 30, 2024 | -$83.87M | -58.7% | -89.0% |
| March 31, 2024 | -$44.37M | +0.0% | +28.4% |
| December 31, 2023 | -$61.96M | -82.7% | -17.8% |
- GALECTIN THERAPEUTICS INC showed a decrease of -22.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2009–2025 period, GALECTIN THERAPEUTICS INC’s stockholders equity has declined by 2763.6% (from -$4.47 million to -$127.92 million).
- The most recent figure is from GALECTIN THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: